NMR studies of group 8 metallodrugs: ¹⁸⁷Os-enriched organo-osmium half-sandwich anticancer complex

Russell J. Needham, Ivan Prokes, Abraha Habtemariam, Isolda Romero-Canelón,[#] Guy J. Clarkson, Peter J. Sadler[†]

Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK. Email: P.J.Sadler@warwick.ac.uk

[#]Current address: School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK

Supporting Information

Tables S1-S2	p 82
Figures S1-S2	p 83, 84

Parameter	Complex 1
Formula	$C_{23}H_{28}BrF_6N_4OsP$
Molar mass /g mol ⁻¹	775.57
Density /mg m ⁻³	1.998
Crystal system	Triclinic
Crystal dimensions /mm	0.60 x 0.40 x 0.14
Space group	P-1
Crystal character	Purple block
a/Å	8.3424(2)
b/Å	12.5262(4)
$c/{ m \AA}$	12.6754(3)
a/deg	85.480(2)
β /deg	79.486(2)
γ/deg	82.407(2)
T/\mathbf{K}	100(2)
Ζ	2
$R[F>4\sigma(F)]$	0.0358
R_{w}	0.0886
GOF	1.038
$\Delta\rho$ max and min /eÅ-3	2.816 & -2.520

Table S1: X-ray crystal structure parameters

Table S2: A2780 human ovarian cancer cytotoxicity of complexes $[Os(\eta^6-p-cym)(N,N-Azpy-NMe_2)X]PF_6$ for a 24 h drug exposure with 72 h recovery time. X = Cl, Br, I.

.8±0.1
40±0.01
18±0.01

^aTaken from reference²⁹



Figure S1: ${}^{13}C - {}^{1}H$ HMQC 2D NMR spectrum of complex 1 in MeCN-*d*₃. Channel F1 ${}^{1}H$, 600 MHz, channel F2 ${}^{13}C$, 150 MHz.



Figure S2: Attempt on direct ¹⁸⁷Os NMR detection for [¹⁸⁷Os]-1 (13.69 MHz). Only baseline noise is present.